Mario Alberto Accardi Sells 8,172 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Key Points

• Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals at an average price of $21.40, resulting in a total transaction of $174,880.80, and now holds 197,394 shares valued at approximately $4.22 million.
• Centessa Pharmaceuticals' stock recently traded down to $21.33, with a 52-week low of $9.60 and a high of $23.24, while its average target price from analysts is $32.44.
• Several institutional investors have significantly increased their stakes in Centessa, with 82.01% of the company's stock now owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Mario Alberto Accardi sold 8,172 shares of the firm's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $21.40, for a total transaction of $174,880.80. Following the sale, the insider owned 197,394 shares in the company, valued at $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Mario Alberto Accardi also recently made the following trade(s):

• On Tuesday, September 9th, Mario Alberto Accardi sold 7,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $20.00, for a total transaction of $140,000.00.
• On Tuesday, July 29th, Mario Alberto Accardi sold 8,322 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.23, for a total transaction of $126,744.06.
• On Tuesday, June 24th, Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA traded down $0.69 on Tuesday, reaching $21.33. The company's stock had a trading volume of 1,159,046 shares, compared to its average volume of 1,405,298. The company has a 50-day simple moving average of $16.90 and a 200 day simple moving average of $14.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $23.24.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 target price for the company. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, September 3rd. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an "outperform" rating and a $40.00 price target on the stock. Chardan Capital restated a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. Finally, Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $32.44.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CNTA. China Universal Asset Management Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company's stock worth $252,000 after acquiring an additional 870 shares during the last quarter. Exome Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 17.0% during the 2nd quarter. Exome Asset Management LLC now owns 166,944 shares of the company's stock worth $2,194,000 after buying an additional 24,200 shares during the last quarter. Octagon Capital Advisors LP lifted its position in shares of Centessa Pharmaceuticals by 24.8% during the 2nd quarter. Octagon Capital Advisors LP now owns 1,030,000 shares of the company's stock worth $13,534,000 after buying an additional 205,000 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Centessa Pharmaceuticals by 3,028.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company's stock worth $460,000 after buying an additional 33,854 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at $16,052,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.